Skip to main content

Table 1 Health state utilities used in the base case analysis

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

Health state Utility (95% CI) Reference
PFS 0.771 (0.731–0.810) 20
PPS 0.612 (0.564–0.659) 20
Death 0 ―
  1. I confidence interval, PFS progression-free survival, PPS post-progression survival